Rotem Eran
Known title: Deputy CEO and CFOCIK: 0001423145
Associated companies
Transaction History
| CLGN | ▲ Buy | Grant | 510,372 | $0 | 9/3/2026 | View on chart |
| CLGN | ▲ Buy | Grant | 510,372 | $0 | 9/3/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
CollPlant Q2 Earnings Miss Estimates Significantly
CollPlant Biotechnologies reported second-quarter results that fell short of analyst expectations. The company posted an adjusted loss of $1.69 per share, missing the estimate of $0.24, while sales of $108,000 were well below the projected $1.466 million. This significant gap between actual performance and market forecasts highlights current operational challenges for the firm.
CollPlant Q2 Earnings Miss Estimates Significantly. CollPlant Biotechnologies reported second-quarter results that fell short of analyst expectations. The company posted an adjusted loss of $1.69 per share, missing the estimate of $0.24, while sales of $108,000 were well below the projected $1.466 million. This significant gap between actual performance and market forecasts highlights current operational challenges for the firm.